Loading clinical trials...
Loading clinical trials...
Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-center Study to Evaluate the Hemodynamic Effects of Riociguat (BAY 63-2521) as Well as Safety and Kinetics in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
Pharmacokinetics parameters were regarded as exploratory parameters. Adverse event data will be covered in Adverse events section.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
Los Angeles, California, United States
San Diego, California, United States
Torrance, California, United States
Westminster, California, United States
Miami, Florida, United States
Iowa City, Iowa, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Rochester, Minnesota, United States
St Louis, Missouri, United States
Start Date
April 14, 2010
Primary Completion Date
June 6, 2012
Completion Date
July 23, 2025
Last Updated
August 28, 2025
202
ACTUAL participants
Riociguat (Adempas, BAY63-2521)
DRUG
Riociguat (Adempas, BAY63-2521)
DRUG
Riociguat (Adempas, BAY63-2521)
DRUG
Placebo
DRUG
Lead Sponsor
Bayer
NCT07079592
NCT05719415
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions